Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics crawled date : 2021 - 12 - 13 save search
Sigilon Therapeutics Announces Strategic Reprioritization
Published: 2021-12-13 (Crawled : 23:00) - globenewswire.com
SGTX | $22.47 -2.56% 0.0% 0
|
Health Technology
|
| O: 0.0%
H: 3.56%
C: -7.83%
therapeutics
Freeline Announces 2022 Corporate Priorities and Guidance
Published: 2021-12-13 (Crawled : 23:00) - globenewswire.com
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: -3.36%
H: 3.7%
C: 0.0%
ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
ORIC | $8.08 -7.87% -8.54% 370K
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: 0.0%
oric-533 ema als potential
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
ft596 therapeutics phase 1 positive t-cell
Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System
Published: 2021-12-13 (Crawled : 22:00) - poseida.com
PSTX | $2.065 -4.4% -4.6% 350K
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: -5.5%
als car-t trials trial clinical trials t-cell
Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 3.04%
H: 5.74%
C: 3.61%
tritac therapeutics platform t-cell
Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
KROS | $56.135 1.71% 1.68% 260K
|
Health Technology
|
| O: -9.67%
H: 1.03%
C: 0.73%
ker-050 ema trial therapeutics preclinical results pre-clinical
Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Trial (EPIPHAST)
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: -3.23%
H: 0.0%
C: 0.0%
aqst-109 drug trial therapeutics epinephrine submission
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 160K
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
phase 2 trial therapeutics immunotherapy potential therapy cancer
Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
SNSE | $0.96 -3.78% -3.93% 55K
|
|
| O: 4.61%
H: 0.0%
C: -6.78%
technology therapeutics index biotech iot nasdaq
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
ALLO | $3.04 -9.79% -10.86% 2.1M
|
Health Technology
|
| O: 1.05%
H: 2.52%
C: -22.56%
allo-715 ema therapeutics positive results phase 1 positive therapy results t-cell
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
ALLO | $3.04 -9.79% -10.86% 2.1M
|
Health Technology
|
| O: 1.05%
H: 2.52%
C: -22.56%
ema als trials trial therapeutics phase 1 positive
Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
VIRX | $0.8367 -1.31% -1.33% 55K
|
Manufacturing
|
| O: -2.86%
H: 0.0%
C: 0.0%
phase 1b therapeutics presentation phase 1 positive phase 2b
Neurona Therapeutics Announces C-Suite Leadership Team
Published: 2021-12-13 (Crawled : 18:00) - biospace.com/
GERN | $3.57 2.0% 1.96% 6.6M
|
Health Technology
|
| O: -0.76%
H: 0.0%
C: 0.0%
therapeutics
Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition
Published: 2021-12-13 (Crawled : 18:00) - biospace.com/
AUTL | $4.23 -5.58% -5.91% 2.7M
|
Health Technology
|
| O: -3.93%
H: 0.0%
C: 0.0%
therapeutics positive cel
Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 16:00) - biospace.com/
PSTX | $2.065 -4.4% -4.6% 350K
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
ema als car-t trials trial therapeutics clinical trials
Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece
Published: 2021-12-13 (Crawled : 16:00) - biospace.com/
ENLV | News | $1.52 15.15% 13.16% 130K
|
Health Technology
|
| O: -2.41%
H: 0.0%
C: 0.0%
covid-19 trial covid authorization
TScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition
Published: 2021-12-13 (Crawled : 15:30) - biospace.com/
TCRX | News 3 d | $7.39 1.79% 1.76% 91K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: 0.0%
ema therapeutics presentation scan
GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and Exposition
Published: 2021-12-13 (Crawled : 15:30) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -12.83%
H: 0.0%
C: 0.0%
gbt0216 health disease positive results phase 1 positive results
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
ft516 fda granted therapeutics phase 1 positive therapy t-cell designation
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.